MDxHealth Appoints Walter Narajowski as Independent Director
GlobeNewswire - Mon Oct 05, 1:36AM CDT
MDxHealth SA (Euronext: MDXH.BR), today announces that it has strengthened its Board of Directors with the appointment of Mr. Walter Narajowski, a medical diagnostics business leader with over 25 years of industry experience.
ROKA: 1.94 (unch), DGX: 63.26 (+0.26)
MDxHealth(R): Completion of the acquisition of NovioGendix - New share capital amount and new number of shares
GlobeNewswire - Fri Sep 18, 10:32AM CDT
MDxHealth SA (Euronext Brussels: MDXH) (the "Company"
MDxHealth's ConfirmMDx Covered by Tufts Health Plan
GlobeNewswire - Thu Sep 17, 12:05AM CDT
MDxHealth SA (Euronext: MDXH.BR) announced that it has signed an agreement with Tufts Health Plan for their government and commercial programs/products. The agreement provides access to ConfirmMDx for Prostate Cancer testing for Tufts Health Plan's 1 million members.
MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering
GlobeNewswire - Tue Sep 15, 12:05AM CDT
-- The acquisition gives MDxHealth access to a validated, non-invasive liquid biopsy test for prostate cancer in the US and EU
MDxHealth Reports New ConfirmMDx Risk Score Data at 11th World Congress on Urological Research
GlobeNewswire - Thu Sep 10, 12:04AM CDT
MDxHealth SA (Euronext: MDXH), today announced data demonstrating that a newly developed algorithm, based on ConfirmMDx test scores (ConfirmMDx Risk Score), stratifies men with DNA methylation positive prostate biopsies for risk of low and high-grade prostate cancer (PCa). The data will be presented at the 11th World Congress on Urological Research in Nijmegen, The Netherlands, 9-11 September 2015 (http://esur-sbur.uroweb.org).
MDxHealth Reports First Half 2015 Results
GlobeNewswire - Thu Aug 20, 12:05AM CDT
-- Revenues up 64% to $7.9 million
MDxHealth Announces Positive Top-Line Data for its Liquid Biopsy Test for Bladder Cancer
GlobeNewswire - Tue Aug 18, 12:06AM CDT
Signs worldwide exclusive agreement with Erasmus MC for bladder cancer DNA methylation markers
MDxHealth Appoints Philip J. Ginsburg M.D. as Chief Medical Officer
GlobeNewswire - Tue Jul 14, 12:06AM CDT
MDxHealth SA (Euronext: MDXH), announced today, the appointment of Philip J. Ginsburg, MD, as Chief Medical Officer (CMO). Dr. Ginsburg joins the company with over 20 years of commercial medical laboratory and urology experience. In this new role, Dr. Ginsburg will have overall responsibility for clinical strategy, including scientific and clinical affairs.
MDxHealth's ConfirmMDx(r) Predicts Prostate Cancer Aggressiveness
GlobeNewswire - Mon May 18, 1:05AM CDT
Epigenetic Health Index Helps Urologists with Prognostic Recommendations
MDxHealth Provides First Quarter 2015 Business Update
GlobeNewswire - Tue May 05, 1:13AM CDT
ConfirmMDx Test Revenue Increases 177% over First Quarter 2014
MDxHealth: Exploiting A Valuation Anomaly Between Exact Sciences And Their European Licensor
VMK Investment Research - at Seeking Alpha - Wed Apr 29, 4:31PM CDT
EXAS: 8.51 (+0.71)
MDxHealth Named Winner of Corporate LiveWire Innovation & Excellence 2015 Award
GlobeNewswire - Fri Apr 24, 2:18AM CDT
MDxHealth SA (Euronext: MDXH.BR) announced today that it has been named as one of the winners of the Corporate LiveWire Innovation & Excellence Awards. The awards are in recognition of innovation and excellence that recipient companies, teams and individuals have shown amid ongoing global economic uncertainty.
MDxHealth Completes Enrollment of Second ConfirmMDx Clinical Utility Study
GlobeNewswire - Mon Apr 20, 1:03AM CDT
MDxHealth SA (Euronext: MDXH.BR) today announced that it has completed patient enrollment into its prospective, randomized PASCUAL clinical utility study with ConfirmMDx for Prostate Cancer. The study, which will evaluate the impact of the ConfirmMDx test results on physician decisions for repeat biopsy, enrolled 600 patients from 17 leading urology practices across the U.S.
MyCartis Announces Appointment of Dr. Jan Groen to Its Board of Directors
PR Newswire Europe - Thu Apr 09, 1:01AM CDT
GHENT, Belgium and LAUSANNE, Switzerland, April 9, 2015 /PRNewswire/ --
MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer
GlobeNewswire - Mon Mar 02, 1:08AM CST
MDxHealth SA (Euronext: MDXH.BR), today announced that data demonstrating the prognostic value of its ConfirmMDx for Prostate Cancer genes and technology was presented at the ASCO Genitourinary Cancers Symposium 2015 in Rosen Shingle Creek, Orlando, Florida, USA (February 26-28, 2015). The data support the ability to predict the presence of clinically significant cancer in biopsy-negative patients based on the DNA hypermethylation of the biomarkers in the ConfirmMDx test.
A European Biotech Stock Basket For 2015
Logribel Biostocks - at Seeking Alpha - Wed Feb 25, 7:05AM CST
VRX: 175.94 (+4.77), SLXP: 172.96 (+0.15), ICPT: 181.90 (-8.81), SPPI: 6.20 (+0.07), EXAS: 8.51 (+0.71)
MDxHealth Named Euronext Best BEL Small Company Performer for 2014
GlobeNewswire - Wed Jan 21, 1:05AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that Euronext granted the 2014 Best BEL Small Company Award, for the highest return among its peers, to MDxHealth. The award was presented to Dr. Jan Groen, CEO of MDxHealth, by M. Pieter De Crem, Secretary of State for Foreign Trade, at a ceremony last night at the Palais de la Bourse in Brussels, Belgium.
MDxHealth Licenses Epigenetic Technology to oncgnostics GmbH for Cervical Cancer Test
GlobeNewswire - Wed Jan 14, 1:06AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has granted a limited worldwide license for its patented methylation specific PCR (MSP) technology to oncgnostics GmbH in Jena, Germany.
MDxHealth CEO Dr Jan Groen to Deliver Keynote Presentation at Biomarkers from Research to Clinic Conference
GlobeNewswire - Mon Jan 05, 1:04AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.